{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:59:01Z","timestamp":1786323541452,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,7,24]],"date-time":"2016-07-24T00:00:00Z","timestamp":1469318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The present study investigated whether the glycoprotein (GP)IIb\/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine\u2010pretreated ST\u2010elevation myocardial infarction (STEMI) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60\u00a0mg. Patients were stratified into four groups, according to morphine and\/or abciximab use. Adenosine diphosphate (ADP)\u2010induced platelet aggregation was measured at four time points: at baseline, and at 2\u00a0h, 1\u00a0day and 2\u00a0days after prasugrel loading.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Morphine use was associated with a three\u2010fold higher level of ADP\u2010induced platelet aggregation 2\u00a0h after prasugrel loading compared with no morphine\/no abciximab (<jats:italic>P<\/jats:italic> = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADP\u2010induced platelet aggregation disappeared (<jats:italic>P<\/jats:italic> = 0.884). This interaction was also seen in the presence of high on\u2010treatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users\/no abciximab users, it was found in only 17\u201320% in the three other groups (<jats:italic>P<\/jats:italic> = 0.003). The effect of morphine disappeared by day 1 \u2013 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The infusion of the GPIIb\/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13053","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T19:40:34Z","timestamp":1467402034000},"page":"1343-1350","source":"Crossref","is-referenced-by-count":28,"title":["Abciximab as a bridging strategy to overcome morphine\u2013prasugrel interaction in STEMI patients"],"prefix":"10.1111","volume":"82","author":[{"given":"Jolanta M.","family":"Siller\u2010Matula","sequence":"first","affiliation":[{"name":"Department of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Specht","sequence":"additional","affiliation":[{"name":"Department of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kubica","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Medicine, Collegium Medicum Nicolaus Copernicus University  Bydgoszcz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology Patras University Hospital  Patras Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[{"name":"Institute of Cardiology \u201cG. d'Annunzio\u201d University \u2013 Chieti\u2010Pescara  Chieti Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva\u2010Luise","family":"Hobl","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Christ","sequence":"additional","affiliation":[{"name":"5<sup>th<\/sup> Medical Department of Cardiology Kaiser Franz Josef Hospital  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-03-0238"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12445"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.068"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.024"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-015-0927-z"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.077"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.05.029"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.06.011"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140310"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102701"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005781"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2013.877581"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.101"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.08.009"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.151233"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181de8b1e"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.021"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.02.030"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv547"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12550"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407024"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv104"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121620"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.05.040"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2016.01.003"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.12.021"},{"key":"e_1_2_10_29_1","first-page":"259","article-title":"Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls","volume":"11","author":"Winter MP","year":"2015","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2015.1095874"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0267"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.833236"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2008.08.018"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.026"},{"key":"e_1_2_10_35_1","first-page":"84","article-title":"Net clinical benefit of prehospital glycoprotein IIb\/IIIa inhibitors in patients with ST\u2010elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score","volume":"24","author":"Hermanides RS","year":"2012","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.880050"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13053","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:18:40Z","timestamp":1694611120000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,24]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/bcp.13053"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13053","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,24]]}}}